---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-032706"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2026-02-02T23:59:59+00:00"
generated_at: "2026-05-16T05:48:45.147268+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Perspective Therapeutics updates corporate presentation with estimated cash balance and pipeline milestones

## Summary
- Estimated cash, cash equivalents and short-term investments as of Dec 31, 2025 disclosed (amount not specified in filing).
- Phase 1/2 data expected across all three clinical programs during 2026.
- VMT-α-NET shows durable disease control and best-in-class safety profile in neuroendocrine tumors.
- VMT01 exhibits preliminary anti-tumor activity at lower doses in melanoma.
- PSV359 targeting FAP-α for solid tumors is ongoing in Phase 1/2a trial.

## SEC filing metadata
- accession: 0001193125-26-032706
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2026-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000119312526032706/0001193125-26-032706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000119312526032706/catx-20260202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-032706
- JSON: https://secwatch.observer/filing/0001193125-26-032706.json
- Plain text: https://secwatch.observer/filing/0001193125-26-032706.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.